Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19219066 | 0.95 | MAPT (0.58) | MAPTLMNACYP2A6NOTUMCYP19A1 | |
| SCHEMBL6685962 | 0.84 | CLK4 (0.64) | MAPTLMNACYP2A6CLK4ADRB2 | |
| SCHEMBL9974945 | 0.84 | MAPT (0.46) | MAPTLMNACYP2A6NOTUMCYP19A1 | |
| SCHEMBL16625771 | 0.81 | CLK4 (0.61) | MAPTLMNACYP2A6CLK4ADRB2 | |
| Pyridine SCHEMBL28854029 | 0.81 | CYP2A6 (0.60) | LMNACYP2A6NOTUMCLK4ADRB2 | |
| SCHEMBL5572579 | 0.80 | MAPT (0.53) | MAPTLMNANOTUMCYP19A1KDM4E | |
| SCHEMBL16614448 | 0.79 | MAPT (0.47) | MAPTLMNACYP2A6NOTUMCYP19A1 | |
| SCHEMBL33833 | 0.79 | NPC1 (0.62) | CYP2A6NOTUMCLK4ADRB2L3MBTL1 | |
| SCHEMBL28062294 | 0.79 | NPC1 (0.62) | CYP2A6NOTUMCLK4ADRB2L3MBTL1 | |
| SCHEMBL21012627 | 0.78 | NOTUM (0.48) | MAPTLMNACYP2A6NOTUMCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907388-A | Synthesis of three-dimensional microporous cadmium compound and application of three-dimensional microporous cadmium compound in pesticide residue pymetrozine detection | 皖西学院 | 2022-08-16 | — | — | CN | claimed |
| CN-107434801-B | 4 '-pyridyl-pyrimidine class compounds of one kind and its synthetic method and application | 南京林业大学 | 2019-08-27 | — | — | CN | claimed |
| CN-107434801-A | A kind of 4 ' pyridyl-pyrimidine class compounds and its synthetic method and application | 南京林业大学 | 2017-12-05 | — | — | CN | claimed |
| EP-1314732-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | claimed |
| EP-0948497-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998024782-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| CN-117561239-A | Pyridinium derivatives prepared by hydrothermal synthesis for use as anode electrolytes in electrochemical cells | 威斯康星州男校友研究基金会 | 2024-02-13 | — | — | CN | disclosed |
| US-20240026218-A1 | METAL-ASSISTED DELAYED FLUORESCENT MATERIALS AS CO-HOST MATERIALS FOR FLUORESCENT OLEDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2024-01-25 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-20240026218-A1 | METAL-ASSISTED DELAYED FLUORESCENT MATERIALS AS CO-HOST MATERIALS FOR FLUORESCENT OLEDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2024-01-25 | — | — | US | disclosed |
| US-11795387-B2 | Metal-assisted delayed fluorescent materials as co-host materials for fluorescent OLEDs | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795387-B2 | Metal-assisted delayed fluorescent materials as co-host materials for fluorescent OLEDs | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| CN-1246856-A | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents | AMGEN INC (US) | 2000-03-08 | — | — | CN | disclosed |
| CN-1236363-A | Process for production of 4-substituted-3-halogeno-1, 4-benzoxazepine derivative and salts thereof | SUNTORY LTD (JP) | 1999-11-24 | — | — | CN | disclosed |
| WO-1999043699-A1 | STREPTOGRAMIN DERIVATIVES, PREPARATION METHOD AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 1999-09-02 | — | — | WO | disclosed |
| EP-0925288-A1 | PROCESS OF PRODUCTION OF 4-SUBSTITUTED-3-HALOGENO-1,4-BENZOXAZEPINE DERIVATIVE AND SALTS THEREOF | SUNTORY LIMITED (JP) | 1999-06-30 | — | — | EP | disclosed |
| WO-1999003847-A1 | PROCESS OF PRODUCTION OF 4-SUBSTITUTED-3-HALOGENO-1,4-BENZOXAZEPINE DERIVATIVE AND SALTS THEREOF | SUNTORY LIMITED (JP) | 1999-01-28 | — | — | WO | disclosed |
| EP-0755930-A1 | BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-01-29 | — | — | EP | disclosed |
| US-4927827-A | Pyridinylpyrimidine derivatives, method for production thereof and a fungicide containing them as the active ingredient | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | MAPT 2789/4885LMNA 1854/4885CYP2A6 1926/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | MAPT 2789/4885LMNA 1854/4885CYP2A6 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.